Clinical characteristics, management and outcomes of enterococcal infective endocarditis: an ancillary study from the ESC-EORP EURO-ENDO registry - 2026
[en] Enterococcal infective endocarditis (EIE) represents a growing proportion of infective endocarditis (IE) cases, particularly among elderly and comorbid patients. EIE poses diagnostic and therapeutic challenges, notably regarding optimal antimicrobial therapy and surgical decision-making. We aimed to compare the clinical characteristics, management, and outcomes of EIE vs. non-enterococcal IE (NEIE) in the ESC-EORP EURO-ENDO registry. Methods and results This ancillary analysis of the prospective EURO-ENDO registry included adult patients with definite or possible IE enrolled between January 2016 and March 2018. Patients with monomicrobial EIE were compared with those with NEIE. Clinical, microbiological, imaging, and therapeutic data were analysed. Multivariable logistic regression including EuroSCORE II and valve status identified independent predictors of in-hospital mortality. Among 3083 patients, 365 (12%) had monomicrobial EIE. Compared with NEIE, EIE patients were older (mean 68 vs. 58 years), had more comorbidities, and more frequent prosthetic valve involvement (41% vs. 26%). Aortic valve localization and colonic uptake on PET/CT were also more common. In-hospital mortality was similar (16% vs. 17%). After adjustment for EuroSCORE II and valve status, EIE was not independently associated with higher in-hospital mortality (adjusted OR 0.67 [95% confidence interval 0.42-1.04]; P = 0.083). Among 195 EIE patients with 1-year follow-up, recurrence occurred in 6%. Healthcare-associated acquisition, prosthetic valve infection, and recurrence were associated with worse outcomes and lower surgical rates. Conclusion EIE affects older, high-risk patients. After adjustment for operative risk, mortality was comparable to other aetiologies, highlighting the need for tailored diagnostic and therapeutic strategies.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Philip, Mary; CHU La Timone, Cardiology, Marseille, France
Gravier Dumonceau, Robinson; APHM, INSERM, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Hop Timone ; Biostatistique et Technologies de l'Information et de la Communication, Aix Marseille University, Marseille, France
Citro, Rodolfo; Department of Cardiology, University of Molise, Campobasso, Italy
Iung, Bernard; Cardiology Department, Bichat Hospital, AP-HP, Paris ; INSERM LVTS, Université Paris-Cité, Paris, France
Kong, William; Department of Cardiology, National University Heart Centre, Singapore, Singapore
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Maggioni, Aldo; Heart Care Foundation, ANMCO Research Center, Florence, Italy
Mancini, Julien; APHM, INSERM, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Hop Timone ; Biostatistique et Technologies de l'Information et de la Communication, Aix Marseille University, Marseille, France
Popescu, Bogdan; Emergency Institute for Cardiovascular Diseases, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania
Prendergast, Bernard; Department of Cardiology, Cleveland Clinic London, London, UK
Sambola, Antonia; Department of Cardiology, Vall d'Hebron University Hospital, Horta-Guinardó, Barcelona, Spain
Sengupta, Shantanu; Department of Cardiology, Sengupta Hospital and Research Institute, Nagpur, India
Timoteo, Ana; Cardiology Department, Santa Marta Hospital, Lisbon, Portugal
Tribouilloy, Christophe; Cardiology, University of Picardie, South Hospital, Amiens, France
Van Melle, Joost; Department of Cardiology, Centre for Congenital Heart Diseases, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands
Giorgi, Roch; APHM, INSERM, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Hop Timone ; Biostatistique et Technologies de l'Information et de la Communication, Aix Marseille University, Marseille, France
Habib, Gilbert; CHU La Timone, Cardiology, Marseille, France
Abbott Vascular Amgen GmbH AstraZeneca Bayer AG Boehringer Ingelheim BSC - Boston Scientific Corporation Pfizer Eli Lilly and Company Merck Novartis Sanofi Servier
Delgado V, Ajmone Marsan N, De Waha S, Bonaros N, Brida M, Burri H, et al 2023 ESC guidelines for the management of endocarditis. Eur Heart J 2023; 44: 3948–4042.
Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132: 1435–1486.
Escolà-Vergé L, Fernández-Hidalgo N, Larrosa MN, Fernandez-Galera R, Almirante B. Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis infective endocarditis at a referral center (2007–2018). Eur J Clin Microbiol Infect Dis 2021; 40: 1137–1148.
Halavaara M, Huotari K, Anttila VJ, Järvinen A. Healthcare-associated infective endocarditis: source of infection and burden of previous healthcare exposure. Antimicrob Steward Healthc Epidemiol 2023; 3: e152.
Lwin N, Bannan A. A retrospective observational study on enterococcal bacteraemia and endocarditis at a regional hospital in New South Wales, Australia. Infect Dis Health 2020; 25: 245–252.
Del Val D, Panagides V, Mestres CA, Miró JM, Rodés-Cabau J. Infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 2023; 81: 394–412.
Pericàs JM, Llopis J, Muñoz P, Gálvez-Acebal J, Kestler M, Valerio M, et al A contemporary picture of enterococcal endocarditis. J Am Coll Cardiol 2020; 75: 482–494.
Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al Enterococcal endocarditis in the beginning of the 21st century: analysis from the international collaboration on endocarditis-prospective cohort study. Clin Microbiol Infect 2013; 19: 1140–1147.
Berge A, Krantz A, Östlund H, Nauclér P, Rasmussen M. The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary. Infection 2019; 47: 45–50.
Bouza E, Kestler M, Beca T, Mariscal G, Rodriguez-Creixems M, Bermejo J, et al The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis 2015; 60: 528–535.
Pérez-Rodríguez MT, Lima O, Garrido M, Rincón A, Martínez-Lamas L, Pérez-González A, et al The role of time to positive blood cultures in enhancing the predictive capability of DENOVA score for diagnosing infective endocarditis in patients with Enterococcus faecalis bacteremia. Eur J Clin Microbiol Infect Dis 2024; 43: 1481–1486.
Danneels P, Chabrun F, Picard L, Martinet P, Rezig S, Lorleac’h A, et al Enterococcus faecalis endocarditis risk assessment in patients with bacteremia: external validation of the DENOVA score. J Infect 2023; 87: 571–573.
Dahl A, Iversen K, Tonder N, Hoest N, Arpi M, Dalsgaard M, et al Prevalence of infective endocarditis in Enterococcus faecalis bacteremia. J Am Coll Cardiol 2019; 74: 193–201.
Danneels P, Hamel JF, Picard L, Rezig S, Martinet P, Lorleac’h A, et al Impact of Enterococcus faecalis endocarditis treatment on risk of relapse. Clin Infect Dis 2023; 76: 281–290.
Østergaard L, Voldstedlund M, Bruun NE, Bundgaard H, Iversen K, Pries-Heje MM, et al Recurrence of bacteremia and infective endocarditis according to bacterial species of index endocarditis episode. Infection 2023; 51: 1739–1747.
Mansur AJ, Dal Bó CMR, Fukushima JT, Issa VS, Grinberg M, Pomerantzeff PMA. Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. Am Heart J 2001; 141: 78–86.
Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, De Alarcón A, et al Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56: 1261–1268.
Freeman L, Milkovits A, McDaniel L, Everson N. Evaluation of penicillin-gentamicin and dual beta-lactam therapies in Enterococcus faecalis infective endocarditis. Int J Antimicrob Agents 2022; 59: 106522.
Saman R, Primus CP, West R, Woldman SJ, Sandoe JAT. Combination therapy versus monotherapy: retrospective analysis of antibiotic treatment of enterococcal endocarditis. BMC Infect Dis 2025; 25: 92.
Ramos-Martínez A, Pericàs JM, Fernández-Cruz A, Muñoz P, Valerio M, Kestler M, et al Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: a prospective cohort study. PLoS One 2020; 15: e0237011.
Pericàs JM, Cervera C, Moreno A, Garcia-de-la-Mària C, Almela M, Falces C, et al Outcome of Enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: preliminary data from a cohort of 78 patients. PLoS One 2018; 13: e0192387.
Habib G, Lancellotti P, Erba PA, Sadeghpour A, Meshaal M, Sambola A, et al The ESC-EORP EURO-ENDO (European infective endocarditis) registry. Eur Heart J Qual Care Clin Outcomes 2019; 5: 202–207.
Pericàs JM, Ambrosioni J, Muñoz P, De Alarcón A, Kestler M, Mari-Hualde A, et al Prevalence of colorectal neoplasms among patients with Enterococcus faecalis endocarditis in the GAMES cohort (2008–2017). Mayo Clin Proc 2021; 96: 132–146.
Escolà-Vergé L, Peghin M, Givone F, Pérez-Rodríguez MT, Suárez-Varela M, Meije Y, et al Prevalence of colorectal disease in Enterococcus faecalis infective endocarditis: results of an observational multicenter study. Rev Esp Cardiol (Engl Ed) 2020; 73: 711–717.
Pericàs JM, Corredoira J, Moreno A, García-País MJ, Falces C, Rabuñal R, et al Relationship between Enterococcus faecalis infective endocarditis and colorectal neoplasm: preliminary results from a cohort of 154 patients. Rev Esp Cardiol (Engl Ed) 2017; 70: 451–458.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) Endorsed by: European association for cardio-thoracic surgery (EACTS), the European association of nuclear medicine (EANM). Eur Heart J 2015; 36: 3075–3128.
Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al EuroSCORE II. Eur J Cardiothorac Surg 2012; 41: 734–745.
Dahl A, Lauridsen TK, Arpi M, Sørensen LL, Østergaard C, Sogaard P, et al Risk factors of endocarditis in patients with Enterococcus faecalis bacteremia: external validation of the NOVA score. Clin Infect Dis 2016; 63: 771–775.
Zakhour J, Allaw F, Kalash S, Wehbe S, Kanj SS. Infective endocarditis after transcatheter aortic valve replacement: challenges in the diagnosis and management. Pathogens 2023; 12: 255.
Mentias A, Girotra S, Desai MY, Horwitz PA, Rossen JD, Saad M, et al Incidence, predictors, and outcomes of endocarditis after transcatheter aortic valve replacement in the United States. JACC Cardiovasc Interv 2020; 13: 1973–1982.
Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Kapadia S, Lerakis S, Cheema AN, et al Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation 2015; 131: 1566–1574.
Pazdernik M, Iung B, Mutlu B, Alla F, Riezebos R, Kong W, et al Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry. Infection 2022; 50: 1191–1202.
Garofoli N, Joly V, Le Pluart D, Hobson CA, Beaumont AL, Lariven S, et al Enterococcal endocarditis management and relapses. JAC Antimicrob Resist 2024; 6: dlae033.
de la Cuesta M, Marin-Cuartas M, de Waha S, Milojevic M, Myers PO, Misfeld M, et al Surgical implications of the 2023 ESC endocarditis guidelines endorsed by EACTS: bridging guidelines and practice. Eur J Cardiothorac Surg 2025; 67: ezaf225.
Pericas JM, Cervera C, Del Rio A, Moreno A, Garcia De La Maria C, Almela M, et al Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect 2014; 20: O1075–O1083.
Peterson SC, Lau TTY, Ensom MHH. Combination of ceftriaxone and ampicillin for the treatment of enterococcal endocarditis: a qualitative systematic review. Ann Pharmacother 2017; 51: 496–503.
Szterenlicht Y, Steinmetz Y, Dadon Z, Wiener-Well Y. Enterococcal infective endocarditis—post discharge treatment with continuous benzylpenicillin and ceftriaxone: a retrospective cohort study. J Infect Chemother 2024; 30: 429–433.
Gil-Navarro MV, Lopez-Cortes LE, Luque-Marquez R, Galvez-Acebal J, Alarcon-Gonzalez A. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis. J Clin Pharm Ther 2018; 43: 220–223.
Beaumont AL, Mestre F, Decaux S, Bertin C, Duval X, Iung B, et al Long-term oral suppressive antimicrobial therapy in infective endocarditis (SATIE study): an observational study. Open Forum Infect Dis 2024; 11: ofae194.
